Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections.

Aguinagalde L, Díez-Martínez R, Yuste J, Royo I, Gil C, Lasa Í, Martín-Fontecha M, Marín-Ramos NI, Ardanuy C, Liñares J, García P, García E, Sánchez-Puelles JM.

J Antimicrob Chemother. 2015 Sep;70(9):2608-17. doi: 10.1093/jac/dkv163. Epub 2015 Jul 4.

PMID:
26142477
2.

Auranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections.

Díez-Martínez R, García-Fernández E, Manzano M, Martínez Á, Domenech M, Vallet-Regí M, García P.

Sci Rep. 2016 Jan 18;6:19525. doi: 10.1038/srep19525.

3.

Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model.

Hegde SS, Okusanya OO, Skinner R, Shaw JP, Obedencio G, Ambrose PG, Blais J, Bhavnani SM.

Antimicrob Agents Chemother. 2012 Mar;56(3):1578-83. doi: 10.1128/AAC.05382-11. Epub 2011 Dec 12.

4.

Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections.

Fernandez J, Hilliard JJ, Morrow BJ, Melton JL, Flamm RK, Barron AM, Lynch AS.

Antimicrob Agents Chemother. 2011 Dec;55(12):5522-8. doi: 10.1128/AAC.00471-11. Epub 2011 Sep 12.

5.

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.

Andes D, Craig WA.

Antimicrob Agents Chemother. 2006 Apr;50(4):1376-83. Erratum in: Antimicrob Agents Chemother. 2014 Apr;58(4):2489. Dosage error in article text.

6.

In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).

Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN.

Clin Infect Dis. 2012 Sep;55 Suppl 3:S206-14. doi: 10.1093/cid/cis563. Review.

PMID:
22903953
7.

In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.

Hilliard JJ, Fernandez J, Melton J, Macielag MJ, Goldschmidt R, Bush K, Abbanat D.

Antimicrob Agents Chemother. 2009 May;53(5):2028-33. doi: 10.1128/AAC.00833-08. Epub 2009 Mar 9.

8.

In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model.

Andes D, Craig W, Nielsen LA, Kristensen HH.

Antimicrob Agents Chemother. 2009 Jul;53(7):3003-9. doi: 10.1128/AAC.01584-08. Epub 2009 May 4.

9.

In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.

Craig WA, Andes DR.

Antimicrob Agents Chemother. 2008 Oct;52(10):3492-6. doi: 10.1128/AAC.01273-07. Epub 2008 Aug 1.

10.

Repurposing auranofin for the treatment of cutaneous staphylococcal infections.

Thangamani S, Mohammad H, Abushahba MF, Sobreira TJ, Seleem MN.

Int J Antimicrob Agents. 2016 Mar;47(3):195-201. doi: 10.1016/j.ijantimicag.2015.12.016. Epub 2016 Jan 23.

11.

DNA binding ligands with in vivo efficacy in murine models of bacterial infection: optimization of internal aromatic amino acids.

Bürli RW, Kaizerman JA, Duan JX, Jones P, Johnson KW, Iwamoto M, Truong K, Hu W, Stanton T, Chen A, Touami S, Gross M, Jiang V, Ge Y, Moser HE.

Bioorg Med Chem Lett. 2004 May 3;14(9):2067-72.

PMID:
15080980
12.

In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.

Karlowsky JA, Adam HJ, Poutanen SM, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):342-7. doi: 10.1016/j.diagmicrobio.2010.10.031.

PMID:
21353963
13.

A comparison of the activity of tigecycline against multiresistant clinical isolates of Staphylococcus aureus and Streptococcus agalactiae.

Sorlozano A, Gutierrez J, Roman E, de Dios Luna J, Roman J, Liebana J, Piedrola G.

Diagn Microbiol Infect Dis. 2007 Aug;58(4):487-9. Epub 2007 May 16.

PMID:
17509803
14.
15.

In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT.

Antimicrob Agents Chemother. 1999 Apr;43(4):738-44.

16.

Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection.

Lewis RE, Klepser ME, Ernst EJ, Lund BC, Biedenbach DJ, Jones RN.

Antimicrob Agents Chemother. 1999 Aug;43(8):2005-9.

17.

Eravacycline (TP-434) is efficacious in animal models of infection.

Grossman TH, Murphy TM, Slee AM, Lofland D, Sutcliffe JA.

Antimicrob Agents Chemother. 2015 May;59(5):2567-71. doi: 10.1128/AAC.04354-14. Epub 2015 Feb 17.

18.

In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates.

Vidaillac C, Parra-Ruiz J, Winterfield P, Rybak MJ.

Int J Antimicrob Agents. 2011 Oct;38(4):301-6. doi: 10.1016/j.ijantimicag.2011.04.023. Epub 2011 Jul 20.

PMID:
21764263
19.

Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection.

Rothstein DM, Farquhar RS, Sirokman K, Sondergaard KL, Hazlett C, Doye AA, Gwathmey JK, Mullin S, van Duzer J, Murphy CK.

Antimicrob Agents Chemother. 2006 Nov;50(11):3658-64. Epub 2006 Aug 28.

20.

Management of osteoarticular infections caused by Staphylococcus aureus is similar to that of other etiologies: analysis of 199 staphylococcal bone and joint infections.

Pääkkönen M, Kallio PE, Kallio MJ, Peltola H.

Pediatr Infect Dis J. 2012 May;31(5):436-8. doi: 10.1097/INF.0b013e31824657dd.

PMID:
22189524

Supplemental Content

Support Center